1 Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver condition worldwide, affecting approximately one-third to nearly 40% of the adult population globally, with projections indicating an increase to over 55% by 2040 ( (THR-) agonist, received approval from the FDA in 2024 for the treatment of adult patients with F2-F3 MASH ( Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained considerable attention in recent years as promising therapeutic agents for MASLD, particularly owing to their well-established efficacy in treating type 2 diabetes mellitus (T2DM) and obesity, conditions closely implicated to MASLD pathogenesis ( This review aims to systematically summarize the mechanistic insights and clinical advances of GLP-1with dual or triple receptor agonists in MASLD treatment, thereby promoting a more profound comprehension and facilitating their application in clinical practice (Figure 1)

Mar 11, 2026 Your compounding pharmacy just offered you semaglutide with niacinamide
Patients who choose to receive and administer medication at home agree to communicate with staff on a weekly and monthly basis
The shape of the lens is important for clear vision, so as the lens becomes more or less swollen, blurred vision can result
Directions for Use: Setu Gluta Fizz should not be swallowed